Propanc Biopharma PPCB 深 滬
已收盤 12-19 16:00:00 美东时间
0.711
-0.009
-1.25%
華盛通- 最 高0.74
- 今 開0.7217
- 成交量 4.41万股
- 最 低 0.70
- 昨 收 0.72
- 總市值 896.70万
- 52周最高 0.8101
- 市盈率 靜 --
- 換手率 0.35%
- 52周最低 0.70
- 委 比 -80.25%
- 總股本 1261.18万
- 歷史最高 0.8101
- 量 比 1.32
- 振 幅 5.56%
- 歷史最低 0.70
- 每 手 1
- 風險率 1.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Friday's After-Market Session
Gainers GT Biopharma (NASDAQ:GTBP) shares moved upwards by 6.6% to $0.65 durin...
12-06 05:05
Propanc Biopharma Submits Request For Foreign Filing License From Spain For Two Provisional Patents To Treat Resistant Cancer, Fibrosis
Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced that it has submitted a request for a
12-01 21:48
Propanc Biopharma, Inc. GAAP EPS of $0.39
Propanc Biopharma, Inc. press release (PPCB): Q1 GAAP EPS of $0.39. More on Propanc Biopharma, Inc. Propanc Biopharma secures up to $100 million private placement Propanc Biopharma announces up to $10...
11-18 00:27
Propanc Biopharma Secures $1M Through Stock Sale
Propanc Biopharma ( ($PPCB) ) has provided an announcement. On November 4, 2025...
11-11 06:55
Propanc Biopharma Plans To Acquire Digital Asset Treasury Companies That Are Trading Below Their Market Capitalization To Net Asset Value
Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced a strategic
11-04 20:21
Propanc Biopharma Secures Up To $100M Strategic Financing From Hexstone Capital Via Series C Preferred Stock
Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it has entered into a strategic financing agreement of up to $100 million with Hexstone Capital LLC ("Hexstone"), a family office that has
10-15 20:47
Propanc Biopharma Announces Plans To Establish A $100M Or Greater Digital Asset Treasury Over The Next Year
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing treatments for recurring and metastatic cancer, announced its fiscal year-end update following the
10-07 20:52
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
Propanc Biopharma, Inc. (Nasdaq: PPCB) has completed its fiscal year-end update and filed its annual 10-K report. The company successfully completed an IPO and uplisted to Nasdaq, with significant financial improvements, including total assets rising to $19.6 million and stockholders’ equity reaching $13.9 million. CEO James Nathanielsz highlighted plans to advance therapeutic candidates and build an intellectual property portfolio, as well as cr...
10-07 12:45
Propanc Biopharma Receives Certificate Of Grant From U.S. Patent & Trademark Office For Its Proenzyme Composition Patent
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a
09-17 20:47
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office
Propanc Biopharma announced the granting of its fourth US patent for "proenzyme composition," specifically capturing a future clinical dose of its lead asset, PRP, targeting metastatic cancer. The company holds 90 patents in major jurisdictions and plans to advance PRP into a Phase 1B study. PRP, as an EMT modulator, uniquely treats cancer without severe side effects, aiming to address the global metastatic cancer market valued at $111.2 billion.
09-17 12:45
